Patents by Inventor Lisa Cannon-Albright

Lisa Cannon-Albright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Depression gene
    Patent number: 7544475
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human depression predisposing gene, specifically the apoptotic protease activating factor 1 (APAF1) gene, some mutant alleles of which cause susceptibility to depression. More specifically, the invention relates to germline mutations in the APAF1 gene and their use in the diagnosis of predisposition to depression. The invention also relates to the prophylaxis and/or therapy of depression associated with a mutation in the APAF1 gene. The invention further relates to the screening of drugs for depression therapy. Finally, the invention relates to the screening of the APAF1 gene for mutations/alterations, which are useful for diagnosing the predisposition to depression.
    Type: Grant
    Filed: May 17, 2007
    Date of Patent: June 9, 2009
    Assignee: IHC Health Services, Inc.
    Inventors: Donna Shattuck, Deanna Russell, Victor Abkevich, Chris Neff, Lisa Cannon-Albright, Nicola Camp
  • DEPRESSION GENE
    Publication number: 20080160519
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human depression predisposing gene, specifically the apoptotic protease activating factor 1 (APAF1) gene, some mutant alleles of which cause susceptibility to depression. More specifically, the invention relates to germline mutations in the APAF1 gene and their use in the diagnosis of predisposition to depression. The invention also relates to the prophylaxis and/or therapy of depression associated with a mutation in the APAF1 gene. The invention further relates to the screening of drugs for depression therapy. Finally, the invention relates to the screening of the APAF1 gene for mutations/alterations, which are useful for diagnosing the predisposition to depression.
    Type: Application
    Filed: May 17, 2007
    Publication date: July 3, 2008
    Applicant: Intermountain Health Care, Inc.
    Inventors: Donna Shattuck, Deanna Russell, Victor Abkevich, Chris Neff, Lisa Cannon-Albright, Nicola Camp
  • Chromosome 17P-linked prostate cancer susceptibility gene
    Patent number: 6844189
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human prostate cancer predisposing gene (HPC2), some alleles of which cause susceptibility to cancer, in particular prostate cancer. More specifically, the present invention relates to germline mutations in the HPC2 gene and their use in the diagnosis of predisposition to prostate cancer. The invention also relates to presymptomatic therapy of individuals who carry deleterious alleles of the HPC2 gene. The invention further relates to somatic mutations in the HPC2 gene in human prostate cancer and their use in the diagnosis and prognosis of human prostate cancer. Additionally, the invention relates to somatic mutations in the HPC2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: January 18, 2005
    Assignees: Myriad Genetics, Inc., University of Utah Research Foundation, Hospital for Sick Children
    Inventors: Sean V. Tavtigian, David H.-F. Teng, Jacques Simard, Johanna M. Rommens, Lisa A. Cannon Albright, Susan L. Neuhausen
  • Methods for detecting predisposition to cancer at the MTS gene
    Patent number: 5989815
    Abstract: The present invention relates to somatic mutations in the Multiple Tumor Suppressor (MTS) gene in human cancers and their use in the diagnosis and prognosis of human cancer. The invention further relates to germ line mutations in the MTS gene and their use in the diagnosis of predisposition to melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, CLL, and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum. The invention also relates to the therapy of human cancers which have a mutation in the MTS gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.
    Type: Grant
    Filed: April 29, 1997
    Date of Patent: November 23, 1999
    Assignees: University of Utah Research Foundation, Myriad Genetics, Inc.
    Inventors: Mark H. Skolnick, Lisa A. Cannon-Albright, Alexander Kamb
  • Germline mutations in the MTS gene
    Patent number: 5624819
    Abstract: The present invention relates to somatic mutations in the Multiple Tumor Suppressor (MTS) gene in human cancers and their use in the diagnosis and prognosis of human cancer. The invention further relates to germ line mutations in the MTS gene and their use in the diagnosis of predisposition to melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, CLL, and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum. The invention also relates to the therapy of human cancers which have a mutation in the MTS gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 29, 1997
    Assignees: University of Utah Research Foundation, Myriad Genetics, Inc.
    Inventors: Mark H. Skolnick, Lisa A. Cannon-Albright, Alexander Kamb